SPTX — Seaport Therapeutics, Inc.

SPTX

HOLD / NEUTRALNeutral

Composite

49.50

Technical

38.10

Fundamental

57.10

Rank

—

Price

20.01

Hurst

—

As of

Nov 3, 2026

Daily

Seaport Therapeutics, Inc.

HealthcareBiotechnology

Seaport Therapeutics is a clinical-stage company developing oral medications for depression, anxiety, and related neuropsychiatric conditions using its proprietary Glyph platform technology. The company's pipeline includes two lead candidates: GlyphAllo, an oral formulation of allopregnanolone for postpartum depression, and GlyphAgo, an oral formulation of agomelatine for anxiety and depression. Founded in 2024 and headquartered in Boston, the company aims to address treatment gaps in these psychiatric disorders.

Market cap

$1.1B

P/E (trailing)

—

P/E (forward)

-7.91

PEG ratio

—

Dividend yield

0.00%

Beta

—

52w range

14.85 – 28.38

Return on equity

—

Profit margin

0.00%

Revenue growth

—

Earnings growth

—

Price history

1Y: 19.75 (-0.5%) · range 15.25–27.84

Cycle position

55/ 100 cycle scoreMID-BULL

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 34 · NOT READY · exit proximity 0

Conviction

49/ 100 · maturity 14%

VScore.0919

Buildup.3070

EMA entry setup.3834

Fundamentals.2357

Volume profile

POC

18.08

Price vs POC

+9.3%

Overhead supply

53%

Runway

+9.2%

Value area 16.34–21.96 · 53% of 120d volume overhead · heavy supply

Get an AI analyst's read on this ticker.Open the AI analyst

Contributing sources

Source	Score	Last seen
earnings-surprise	0.967	Nov 3, 2026

Forward returns

Not yet labeled — the study prices these as positions mature.